These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2574454)

  • 1. The potential of positron-emission tomography for pharmacokinetic and pharmacodynamic studies of neuroleptics.
    Farde L; Wiesel FA; Nilsson L; Sedvall G
    Psychopharmacol Ser; 1989; 7():32-9. PubMed ID: 2574454
    [No Abstract]   [Full Text] [Related]  

  • 2. Brain dopamine receptors in schizophrenia: PET problems.
    Seeman P
    Arch Gen Psychiatry; 1988 Jun; 45(6):598-600. PubMed ID: 3259865
    [No Abstract]   [Full Text] [Related]  

  • 3. PET studies of dopamine receptors in relation to antipsychotic drug treatment.
    Farde L; Nordström AL; Halldin C; Wiesel FA; Sedvall G
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():468A-469A. PubMed ID: 1354052
    [No Abstract]   [Full Text] [Related]  

  • 4. Central D1- and D2-receptor occupancy during antipsychotic drug treatment.
    Wiesel FA; Farde L; Nordström AL; Sedvall G
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):759-67. PubMed ID: 1981395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevation of dopamine D2 receptors in schizophrenia is underestimated by radioactive raclopride.
    Seeman P; Niznik HB; Guan HC
    Arch Gen Psychiatry; 1990 Dec; 47(12):1170-2. PubMed ID: 2244801
    [No Abstract]   [Full Text] [Related]  

  • 6. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain.
    Seeman P; Guan HC; Niznik HB
    Synapse; 1989; 3(1):96-7. PubMed ID: 2521961
    [No Abstract]   [Full Text] [Related]  

  • 7. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.
    Farde L; Nordström AL; Wiesel FA; Pauli S; Halldin C; Sedvall G
    Arch Gen Psychiatry; 1992 Jul; 49(7):538-44. PubMed ID: 1352677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography of brain dopamine D-2 receptors with 11C-raclopride in early Parkinson's disease.
    Laihinen A; Rinne JO; Någren K; Bergman J; Haaparanta M; Solin O; Ruotsalainen U; Rinne UK
    Acta Radiol Suppl; 1991; 376():151. PubMed ID: 1666759
    [No Abstract]   [Full Text] [Related]  

  • 9. Sight and insight: brain dopamine receptor occupancy by neuroleptics visualised in living schizophrenic patients by positron emission tomography.
    Waddington JL
    Br J Psychiatry; 1989 Apr; 154():433-6. PubMed ID: 2574067
    [No Abstract]   [Full Text] [Related]  

  • 10. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.
    Farde L; Wiesel FA; Stone-Elander S; Halldin C; Nordström AL; Hall H; Sedvall G
    Arch Gen Psychiatry; 1990 Mar; 47(3):213-9. PubMed ID: 1968328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical melperone treatment blocks D2-dopamine receptors in the human brain as determined by PET.
    Wiesel FA; Farde L; Halldin C
    Acta Psychiatr Scand Suppl; 1989; 352():30-4. PubMed ID: 2573239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET studies of neuroreceptors in schizophrenia. Commentary on "The current status of PET scanning with respect to schizophrenia".
    Wong DF
    Neuropsychopharmacology; 1992 Aug; 7(1):69-72; discussion 73-5. PubMed ID: 1388023
    [No Abstract]   [Full Text] [Related]  

  • 13. Elevated D2 in schizophrenia: role of endogenous dopamine and cerebellum. Commentary on "The current status of PET scanning with respect to schizophrenia".
    Seeman P
    Neuropsychopharmacology; 1992 Aug; 7(1):55-7; discussion 73-5. PubMed ID: 1388022
    [No Abstract]   [Full Text] [Related]  

  • 14. The relationship between risperidone plasma levels and dopamine D2 occupancy: a positron emission tomographic study.
    Remington G; Kapur S; Zipursky R
    J Clin Psychopharmacol; 1998 Feb; 18(1):82-3. PubMed ID: 9472848
    [No Abstract]   [Full Text] [Related]  

  • 15. Raclopride, a new selective ligand for the dopamine-D2 receptors.
    Hall H; Köhler C; Gawell L; Farde L; Sedvall G
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(5):559-68. PubMed ID: 2975809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic analysis of receptor binding with positron emission tomography.
    Eriksson L; Farde L; Rosenquist G
    Acta Radiol Suppl; 1991; 376():126-7. PubMed ID: 1666746
    [No Abstract]   [Full Text] [Related]  

  • 17. Distribution of remoxipride to the human brain and central D2-dopamine receptor binding examined in vivo by PET.
    Farde L; von Bahr C
    Acta Psychiatr Scand Suppl; 1990; 358():67-71. PubMed ID: 1978494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No D2 receptor increase in PET study of schizophrenia.
    Farde L; Wiesel FA; Hall H; Halldin C; Stone-Elander S; Sedvall G
    Arch Gen Psychiatry; 1987 Jul; 44(7):671-2. PubMed ID: 2955770
    [No Abstract]   [Full Text] [Related]  

  • 19. SPECT technique for visualization of cerebral dopamine D2 receptors.
    Konig P; Benzer MK; Fritzche H
    Am J Psychiatry; 1991 Nov; 148(11):1607-8. PubMed ID: 1681752
    [No Abstract]   [Full Text] [Related]  

  • 20. In vivo dopamine receptor assessment for clinical studies using positron emission tomography.
    Swart JA; Korf J
    Biochem Pharmacol; 1987 Jul; 36(14):2241-50. PubMed ID: 2886125
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.